Centessa Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Centessa Pharmaceuticals CEO'su Saurabh Saha, Jan2021 tarihinde atandı, in görev süresi 3.83 yıldır. in toplam yıllık tazminatı $ 2.71M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.1% maaş ve 75.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.4% ine doğrudan sahiptir ve bu hisseler $ 8.98M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 3.8 yıldır.

Anahtar bilgiler

Saurabh Saha

İcra Kurulu Başkanı

US$2.7m

Toplam tazminat

CEO maaş yüzdesi	24.1%
CEO görev süresi	3.8yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?

Nov 14

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

Sep 25

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Aug 15

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Apr 24

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Mar 07

CEO Tazminat Analizi

Saurabh Saha'un ücretlendirmesi Centessa Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$161m
Jun 30 2024	n/a	n/a	-US$157m
Mar 31 2024	n/a	n/a	-US$138m
Dec 31 2023	US$3m	US$652k	-US$151m
Sep 30 2023	n/a	n/a	-US$157m
Jun 30 2023	n/a	n/a	-US$173m
Mar 31 2023	n/a	n/a	-US$212m
Dec 31 2022	US$10m	US$621k	-US$216m
Sep 30 2022	n/a	n/a	-US$234m
Jun 30 2022	n/a	n/a	-US$220m
Mar 31 2022	n/a	n/a	-US$197m
Dec 31 2021	US$16m	US$573k	-US$381m

Tazminat ve Piyasa: Saurabh 'nin toplam tazminatı ($USD 2.71M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.54M ).

Tazminat ve Kazançlar: Saurabh 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Saurabh Saha (48 yo)

3.8yrs

Görev süresi

US$2,705,874

Tazminat

Dr. Saurabh Saha, M. D., Ph. D. serves as an Independent Director at Clarivate Plc since May 04, 2023. He serves as the Chief Executive Officer at Centessa Pharmaceuticals plc (formerly Centessa Pharmaceut...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Saurabh Saha	CEO & Director	3.8yrs	US$2.71m	0.40% $ 9.0m
David Chao	Chief Administrative Officer	3.6yrs	US$1.32m	0.10% $ 2.3m
John Crowley	CFO and Principal Financial & Accounting Officer	less than a year	Veri yok	Veri yok
Tia Bush	Chief Technology & Quality Officer	1.3yrs	Veri yok	0.059% $ 1.3m
Kristen Sheppard	Senior Vice President of Investor Relations & Corporate Communications	2.4yrs	Veri yok	Veri yok
Iqbal Hussain	General Counsel	3.8yrs	Veri yok	0.071% $ 1.6m
Karen Anderson	Chief People Officer	2yrs	Veri yok	0.054% $ 1.2m
Gregory Weinhoff	Chief Business Officer	less than a year	US$3.31m	0.054% $ 1.2m
Mario Accardi	President of the Orexin Program	less than a year	Veri yok	Veri yok
Ellie Im	Senior Vice President of Clinical Development & Oncology	1.1yrs	Veri yok	Veri yok
Charlene Stoudt	Senior Vice President of Clinical Development Operations	less than a year	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: CNTA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Saurabh Saha	CEO & Director	3.8yrs	US$2.71m	0.40% $ 9.0m
Francesco de Rubertis	Independent Non-Executive Chairman of the Board	4yrs	Veri yok	Veri yok
Mary Hedley	Independent Non-Executive Director	3.8yrs	US$252.69k	0% $ 0
Brett I. Zbar	Independent Non-Executive Director	3.8yrs	US$257.69k	0% $ 0
Arjun Goyal	Independent Non-Executive Director	3.8yrs	US$260.19k	0% $ 0
Samarth Kulkarni	Independent Non-Executive Director	3.8yrs	US$255.19k	0% $ 0
Carol Stuckley	Independent Non-Executive Director	3.5yrs	US$262.69k	0% $ 0
Mathias Hukkelhoven	Independent Non-Executive Director	2.3yrs	US$247.69k	0% $ 0

3.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CNTA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Centessa Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO & Director recently sold US$929k worth of stock

CEO & Director recently sold US$864k worth of stock

CEO & Director notifies of intention to sell stock

Chief Business Officer recently sold US$261k worth of stock

CEO & Director notifies of intention to sell stock

Chief Business Officer notifies of intention to sell stock

Recent updates

CEO & Director recently sold US$929k worth of stock

New major risk - Revenue and earnings growth

Price target increased by 8.2% to US$28.29

Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?

Centessa Pharmaceuticals Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist

CEO & Director recently sold US$864k worth of stock

CEO & Director notifies of intention to sell stock

Chief Business Officer recently sold US$261k worth of stock

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

CEO & Director notifies of intention to sell stock

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $150 million.

Chief Business Officer notifies of intention to sell stock

Price target increased by 10% to US$16.00

Centessa Pharmaceuticals plc Announces Positive Interim Phase 1 Clinical Data with Its Novel Orexin Receptor 2 (OX2R) Agonist, Orx750, in Acutely Sleep-Deprived Healthy Volunteers

CEO & Director notifies of intention to sell stock

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Price target increased by 9.2% to US$14.20

Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes

Insufficient new directors

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc Announces Open IND for ORX750

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

New major risk - Revenue and earnings growth

Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia

Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors

Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Insider notifies of intention to sell stock

World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc

New major risk - Revenue and earnings growth

Price target increased by 18% to US$7.08

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors

New minor risk - Share price stability

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for Serpinpc for Hemophilia B

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Centessa Pharmaceuticals plc Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension of Phase 2a Study of SerpinPC for Hemophilia

Centessa Pharmaceuticals Announces Karen Anderson as New Chief People Officer

Price target decreased to US$6.00

High number of new and inexperienced directors

The Law Offices of Vincent Wong Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc

Centessa Pharmaceuticals snaps multi-day losing streak; up 10%

Centessa Pharmaceuticals plc Announces Departure of Javad Shahidi as Chief Medical Officer

Centessa Pharmaceuticals plc Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index

Centessa Pharmaceuticals GAAP EPS of -$0.69

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, Phd, as Senior Vice President of Regulatory Affairs

Centessa Pharmaceuticals plc Announces Executive Changes

Centessa Pharmaceuticals plc Announces Board Changes

Centessa Pharmaceuticals plc Announces Poster Presentation of First Preclinical Data for LockBody Program At 2022 ASCO Annual Meeting

Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Centessa Pharmaceuticals plc, Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Centessa Pharmaceuticals Doses First Subject in Global Phase 3 Action Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

Centessa Pharmaceuticals Limited Announces Resignation of Robert M. Califf as Member of the Board of Directors

Checking In On Centessa Pharmaceuticals

Centessa Pharmaceuticals plc Together with Subsidiary Palladio Biosciences, Inc. Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease and Reports Initial Positive Safety Data from ALERT Study

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş